RxDoctor Payments Data

Praveen Datar, MD

Pulmonary Disease · West Plains, MONPI 1053734657

Payments from drug & device makers

$9,273in general payments, 2019–2025

Across 106 payments — averaging $87.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • GSK$465
  • Merit Medical Systems Inc$353
  • Johnson & Johnson$216
  • Boehringer Ingelheim$156
  • Actelion Pharmaceuticals US, Inc.$147
  • plus $428 from 12 others

What the payments were for

  • Travel & lodging$4,79252%
  • Food & beverage$1,48016%
  • Education$3,00032%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,273 in reported general payments places this provider in the 70th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$66,756
Medicare patients
335
Services billed
802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fasenra PenBenralizumab47$254,355
Trelegy ElliptaFluticasone/Umeclidin/Vilanter343$248,257
XolairOmalizumab53$171,855
Breztri AerosphereBudesonide/Glycopyr/Formoterol204$143,814
NucalaMepolizumab18$84,005
Spiriva HandihalerTiotropium Bromide108$60,665
Stiolto RespimatTiotropium Br/Olodaterol Hcl105$56,966
Spiriva RespimatTiotropium Bromide80$52,219
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr108$51,896
Dupixent PenDupilumab13$48,589
Incruse ElliptaUmeclidinium Bromide71$29,356
SymbicortBudesonide/Formoterol Fumarate114$28,431
Breo ElliptaFluticasone/Vilanterol70$27,407
Advair HfaFluticasone Propion/Salmeterol73$25,389
EliquisApixaban38$24,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$465$450,754657 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$144$193,696361 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$156$120,308207 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in West Plains

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →